CCR5 and neoplasm: For instance, CCR5 ligands (CCL3, CCL4, CCL5) have been shown to induce the proliferation of CCR5-expressing MDSCs in the bone marrow, while CCL5 deficiency adversely modulated the morphology, differentiation, and immunosuppressive activity of MDSCs, ultimately inhibiting tumor growth 15.